171 related articles for article (PubMed ID: 37331225)
1. Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.
Sriskandarajah P; McLornan DP; Oni C; Wilson AJ; Woodley C; Ciesielska M; Raj K; Dillon R; Ethell M; Chacko J; Orchard K; Radia DH
Curr Res Transl Med; 2023; 71(3):103398. PubMed ID: 37331225
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
[TBL] [Abstract][Full Text] [Related]
3. Avapritinib for Systemic Mastocytosis.
Bose P; Verstovsek S
Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
5. Avapritinib for advanced systemic mastocytosis.
Gotlib J; Reiter A; DeAngelo DJ
Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.
Veitch S; Radia DH
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201389
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ; Radia DH; George TI; Robinson WA; Quiery AT; Drummond MW; Bose P; Hexner EO; Winton EF; Horny HP; Tugnait M; Schmidt-Kittler O; Evans EK; Lin HM; Mar BG; Verstovsek S; Deininger MW; Gotlib J
Nat Med; 2021 Dec; 27(12):2183-2191. PubMed ID: 34873347
[TBL] [Abstract][Full Text] [Related]
8. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
Pardanani A; Reichard K; Tefferi A
Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
[TBL] [Abstract][Full Text] [Related]
9. The Role of Avapritinib for the Treatment of Systemic Mastocytosis.
Sumbly V; Landry I; Iqbal S; Bhatti Z; Alshamam MS; Ashfaq S; Rizzo V
Cureus; 2021 Sep; 13(9):e18385. PubMed ID: 34729266
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J; Reiter A; Radia DH; Deininger MW; George TI; Panse J; Vannucchi AM; Platzbecker U; Alvarez-Twose I; Mital A; Hermine O; Dybedal I; Hexner EO; Hicks LK; Span L; Mesa R; Bose P; Pettit KM; Heaney ML; Oh ST; Sen J; Lin HM; Mar BG; DeAngelo DJ
Nat Med; 2021 Dec; 27(12):2192-2199. PubMed ID: 34873345
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic efficacy profiles of avapritinib and nintedanib in
Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
[TBL] [Abstract][Full Text] [Related]
12. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
13. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis.
Mannelli F; Crupi F; Zanotti R; Pagano L; Rapezzi D; Tanasi I; Criscuolo M; Bonifacio M; Fresa A; Guglielmelli P; Vannucchi AM
Ther Adv Hematol; 2023; 14():20406207231205643. PubMed ID: 37929078
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.
Reiter A; Gotlib J; Álvarez-Twose I; Radia DH; Lübke J; Bobbili PJ; Wang A; Norregaard C; Dimitrijevic S; Sullivan E; Louie-Gao M; Schwaab J; Galinsky IA; Perkins C; Sperr WR; Sriskandarajah P; Chin A; Sendhil SR; Duh MS; Valent P; DeAngelo DJ
Leukemia; 2022 Aug; 36(8):2108-2120. PubMed ID: 35790816
[TBL] [Abstract][Full Text] [Related]
15. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
Tashi T; Deininger MW
Immunol Allergy Clin North Am; 2023 Nov; 43(4):723-741. PubMed ID: 37758409
[TBL] [Abstract][Full Text] [Related]
16. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Pilkington H; Smith S; Roskell N; Iannazzo S
Future Oncol; 2022 Apr; 18(13):1583-1594. PubMed ID: 35114819
[TBL] [Abstract][Full Text] [Related]
17. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
18. CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in
Schneeweiss-Gleixner M; Filik Y; Stefanzl G; Berger D; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Witzeneder N; Greiner G; Hoermann G; Schiefer AI; Schwaab J; Jawhar M; Reiter A; Sperr WR; Arock M; Valent P; Gleixner KV
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804842
[TBL] [Abstract][Full Text] [Related]
19. Precision Medicine in Systemic Mastocytosis.
Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
[TBL] [Abstract][Full Text] [Related]
20. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
